Mild Cognitive Impairment. Mild cognitive disorder
Conditions
Interventions
Intervention 1: Intervention group: Capsule containing 1 gram of dry sesame seed extract, administered once daily for 12 weeks (Manufactured by: Giyah Kala Company, Iran). Intervention 2: Control grou
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: Individuals aged 50 to 75 years Written informed consent after full explanation of the study objectives Montreal Cognitive Assessment (MoCA) score of 18-25 Clinical Dementia Rating (CDR) score of 0.5 Body Mass Index (BMI) between 23 and 35 Ability to read and write Fluency in Persian language Physical and mental ability to participate in the study and complete the assessments
Exclusion criteria
Exclusion criteria: History of Stroke or Other Cerebrovascular Disorders Diagnosis of Alzheimer's Disease or Dementia Presence of Brain Tumors or Other Structural Brain Lesions Severe Psychiatric Disorders Such as Major Depression or Bipolar Disorder Epilepsy, Mental Retardation, Parkinson's Disease, Multiple Sclerosis (MS), Severe Renal, Hepatic, or Cardiac Disorders, Hematologic Malignancies, Endocrine Disorders Such as Uncontrolled Diabetes or Severe Hypothyroidism/Hyperthyroidism, and Major Gastrointestinal Problems Participants with Pacemakers, Intracranial Metal Objects, or a History of Brain Surgery, Aneurysm Clips, Artificial Heart Valves, Cochlear Implants, Metal Fragments, or Foreign Bodies in the Eyes, Skin, or Body Alcohol and Substance Abuse Consumption of Sesame Oil, Olive Oil, Coconut Oil, Fish Oil, or Omega-3 Due to Their Documented Cognitive Effects Regular Consumption (More Than 30 Grams per Week) of Tahini or Other Sesame-Based Products (e.g., Halvah) During the Three Months Prior to the Intervention Use of Memory-Enhancing or Concentration-Enhancing Medications Known Allergy or Hypersensitivity to, Sesame or Sesame Oil Participation in Other Clinical Trials Within the Past Three Months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor Necrosis Factor Alpha. Timepoint: At baseline (prior to intervention initiation) and at 12 weeks post-intervention. Method of measurement: Tumor Necrosis Factor Alpha ELISA kit.;Interleukin-6. Timepoint: At baseline (prior to intervention initiation) and at 12 weeks post-intervention. Method of measurement: Interleukin-6 ELISA kit.;Malondialdehyde. Timepoint: At baseline (prior to intervention initiation) and at 12 weeks post-intervention. Method of measurement: Thiobarbituric acid method.;Total Antioxidant Capacity. Timepoint: At baseline (prior to intervention initiation) and at 12 weeks post-intervention. Method of measurement: Spectrophotometer.;Montreal Cognitive Assessment (MoCA) score. Timepoint: At baseline (prior to intervention initiation) and at 12 weeks post-intervention. Method of measurement: Montreal Cognitive Assessment (MoCA). | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep Quality. Timepoint: At baseline (prior to intervention initiation) and at 12 weeks post-intervention. Method of measurement: Pittsburgh Sleep Quality Index (PSQI).;Depression. Timepoint: At baseline (prior to intervention initiation) and at 12 weeks post-intervention. Method of measurement: Geriatric Depression Scale (GDS). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAnahita Mansouri
Ahvaz University of Medical Sciences
Outcome results
None listed